1. Search Result
Search Result
Results for "

Immune-mediated

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

3

Peptides

6

Inhibitory Antibodies

4

Natural
Products

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3502

    RA101495; RA3193

    Complement System Inflammation/Immunology
    Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan can be used in research of immune-mediated necrotising myopathy (IMNM) .
    Zilucoplan
  • HY-B0890

    McN-2783-21-98

    PGE synthase Inflammation/Immunology
    Zomepirac sodium salt (McN-2783-21-98) is a potent prostaglandin biosynthesis inhibitor. Zomepirac sodium salt is a non-steroidal anti-inflammatory drug (NSAID). Zomepirac sodium salt can cause immune-mediated liver injury .
    Zomepirac sodium salt
  • HY-N3702

    Syk Inflammation/Immunology
    Dehydroabietinol is an abietane diterpenoid. Dehydroabietinol has kinase inhibition activity for spleen tyrosine kinase (SYK) with an IC50 value of 46.4 μM. Dehydroabietinol can be used for the research of immune-mediated disease .
    Dehydroabietinol
  • HY-N15730

    Drug Derivative Inflammation/Immunology
    3-Hydroxymycophenolic acid (Compound 5) is a microbial transformation product of Mycophenolic acid (HY-B0421) by Cunninghamella echinulata. 3-Hydroxymycophenolic acid has low cytotoxicity against AGS cells and fibroblasts. 3-Hydroxymycophenolic acid can be used for immune-mediated renal diseases research .
    3-Hydroxymycophenolic acid
  • HY-175751

    PROTACs PI5P4K Cancer
    LRK-4189 (Compound 319) is an orally active and selective PIP4K2C PROTAC degrader with a DC50 < 500 nM for PIP4K2C in MOLT-4 cells. LRK-4189 has an antitumor activity and induces intrinsic cell death and activates interferon signaling, therefore triggering immune-mediated tumor killing in immune-inert microsatellite stable (MSS) CRC cells. LRK-4189 can be used for cancers like MSS colorectal carcinoma research .
    LRK-4189
  • HY-B0890A

    PGE synthase Inflammation/Immunology
    Zomepirac (McN-2783-21-98) is a potent prostaglandin biosynthesis inhibitor. Zomepirac is a non-steroidal anti-inflammatory drug (NSAID). Zomepirac can cause immune-mediated liver injury .
    Zomepirac
  • HY-P991150

    Interleukin Related Inflammation/Immunology
    Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
    Ompekimig
  • HY-P3502A

    RA101495 TFA; RA3193 TFA

    Complement System Inflammation/Immunology
    Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan TFA can be used in research of immune-mediated necrotising myopathy (IMNM) .
    Zilucoplan TFA
  • HY-20070

    TNF Receptor Others Inflammation/Immunology
    BMS-566394 is a potent inhibitor of tumor necrosis factor-α (TNF-α) converting enzyme (TACE) that helps reduce the production of TNF-α, thereby alleviating inflammation and immune-mediated diseases and can be used in the study of inflammatory and autoimmune diseases .
    BMS-566394
  • HY-B0890R

    PGE synthase Inflammation/Immunology
    Zomepirac (sodium salt) (Standard) is the analytical standard of Zomepirac (sodium salt). This product is intended for research and analytical applications. Zomepirac sodium salt (McN-2783-21-98) is a potent prostaglandin biosynthesis inhibitor. Zomepirac sodium salt is a non-steroidal anti-inflammatory drug (NSAID). Zomepirac sodium salt can cause immune-mediated liver injury .
    Zomepirac sodium salt (Standard)
  • HY-155100

    STING Inflammation/Immunology Cancer
    BI 7446 is a cyclic dinucleotide (CDN)-based potent and selective stimulator of interferon genes (STING) agonist. BI 7446 can activate all five STING variants in cells and induce tumor-specific immune-mediated tumor rejection. BI 7446 can be used for immuno-oncology research .
    BI 7446
  • HY-176265

    CD28 Inflammation/Immunology
    DDS5 is a CD28 inhibitor with a kd of 175.57 µM. DDS5 significantly inhibits CD28-CD80 interaction (IC50: 332 µM). DDS5 can be used for research of immune-mediated diseases, including inflammatory bowel disease and rheumatoid arthritis .
    DDS5
  • HY-117786

    PKC Neurological Disease
    Go 7874 is a protein kinase C (PKC) inhibitor. Go 7874 mediated neuroprotection against LPS/IFNg-induced neuronal cell death in an immune-mediated neurotoxicity model, not through PKC activity. In contrast, the neuroprotective mechanism of Go 7874 involves inhibition of inducible nitric oxide synthase (iNOS) gene expression, followed by reduced nitric oxide (NO) production .
    Go 7874
  • HY-178763

    JAK Inflammation/Immunology
    DEL1187-126-28-16 is a JAK3 inhibitor with IC50s of 10 and 0.97 nM against JAK3 WT in 0 and 60 min. DEL1187-126-28-16 has no activity at all towards the C909S mutant, JAK1, JAK2, and TYK2. DEL1187-126-28-16 can be used for the study of immune-mediated diseases .
    DEL1187-126-28-16
  • HY-P99340
    Sotrovimab
    4 Publications Verification

    VIR 7831; GSK-4182136

    SARS-CoV Infection Cancer
    Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
    Sotrovimab
  • HY-178755

    JAK Inflammation/Immunology
    DEL1187-126-5-80 is a JAK3 inhibitor with IC50s of 52 and 7.9 nM against JAK3 WT in 0 and 60 min. DEL1187-126-5-80 has no activity at all towards the C909S mutant, JAK1, JAK2, and TYK2. DEL1187-126-5-80 can be used for the study of immune-mediated diseases .
    DEL1187-126-5-80
  • HY-120214

    Syk RET Inflammation/Immunology
    TAS05567 is a potent, highly selective, ATP-competitive and orally active Syk inhibitor with an IC50 of 0.37 nM. In a panel of 192 kinases, TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, JAK2, KDR and RET with IC50s of 10 nM, 4.8 nM, 600 nM and 29 nM, respectively). TAS05567 can be used for humoral immune-mediated inflammatory conditions such as autoimmune and allergic diseases .
    TAS05567
  • HY-153358A

    HDAC Cancer
    (S)-TNG260 is an isomer of TNG260 (HY-153358). TNG260 is a CoREST selective deacetylase (CoreDAC) inhibitor. TNG260 inhibits HDAC1 with 10-fold selectivity over HDAC3. TNG260 causes HDAC1 inhibition and reverses anti-PD1 resistance driven by STK11 deletion. TNG260 reduces intratumoral infiltration of neutrophils. TNG260 exhibits immune-mediated cell killing.
    (S)-TNG260
  • HY-172803

    Ferroptosis ERK MEK p38 MAPK Inflammation/Immunology
    Ferroptosis inducer-7 is an orally active and selective ferroptosis inducer via inositol 1,4,5-trisphosphate receptor (IP3R)/calcium release-activated calcium channel protein (ORAI). Ferroptosis inducer-7 exhibits a notable effect in alleviating anemia symptoms, suppressing bone marrow CTLs activation, and improving hematopoietic function in immune-mediated bone marrow failure. Ferroptosis inducer-7 can be studied in research for aplastic anemia .
    Ferroptosis inducer-7
  • HY-173462

    IKK Cancer
    TBK1-IN-2 (Compound A1) is a potent TBK1 inhibitor (IC50: 775 pM). TBK1-IN-2 binds to TBK1 through stable hydrogen bonds and π-π stacking, inhibiting IRF3 phosphorylation. TBK1-IN-2 synergizes with TNF/IFNγ to enhance immune-mediated tumor cell death. TBK1-IN-2 can be used in cancer immunotherapy research .
    TBK1-IN-2
  • HY-P991510

    TNF Receptor Cancer
    CDX-1140 is a human IgG2 CD40 agonist antibody. CDX-1140 activates dendritic cells (DCs) and B cells and drives NF-kB stimulation in a CD40-expressing reporter cell line. CDX-1140 is independent of FcR binding and synergistic with native CD40L signaling. CDX-1140 has both direct and immune-mediated anti-tumor activity. CDX-1140 can be used for the study of lymphoma cancer and solid tumors .
    CDX-1140
  • HY-12512
    cGAMP
    Maximum Cited Publications
    18 Publications Verification

    Cyclic GMP-AMP; 3',3'-cGAMP

    STING Inflammation/Immunology
    cGAMP (Cyclic GMP-AMP) functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators .
    cGAMP
  • HY-110385
    cGAMP disodium
    Maximum Cited Publications
    18 Publications Verification

    Cyclic GMP-AMP disodium; 3',3'-cGAMP disodium

    STING Endogenous Metabolite Inflammation/Immunology
    cGAMP (Cyclic GMP-AMP) disodium functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP diammonium activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators .
    cGAMP disodium
  • HY-110385A
    cGAMP diammonium
    Maximum Cited Publications
    18 Publications Verification

    Cyclic GMP-AMP diammonium; 3',3'-cGAMP diammonium

    STING Endogenous Metabolite Inflammation/Immunology
    cGAMP (Cyclic GMP-AMP) diammonium functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP diammonium activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators .
    cGAMP diammonium
  • HY-162065
    N6F11
    1 Publications Verification

    Ferroptosis Cancer
    N6F11 is a selective ferroptosis inducer, and can selectively induce ferroptosis by targeting TRIM25-mediated GPX4 degradation in cancer cells while sparing immune cells. N6F11 initiates HMGB1-dependent antitumor immunity mediated by CD8 + T cells .
    N6F11
  • HY-P10056

    Human ezrin peptide (324-337)

    HIV HCV HPV Influenza Virus Interleukin Related Infection Inflammation/Immunology
    HEP-1 (Human ezrin peptide (324 - 337)) is an orally active peptide with antiviral, anti-inflammatory, and immunomodulatory activities. HEP-1 is effective against infections by various viruses such as HIV, HCV, herpes viruses, HPV, and influenza viruses. As an immunomodulator, HEP-1 can enhance the adaptive immunity mediated by B cells and T cells. HEP-1 can also increase the antibody titers after hepatitis B vaccination. HEP-1 can be used in the research of viral infections and inflammation-related diseases .
    HEP-1
  • HY-P99966

    RANKL/RANK Cancer
    Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) .
    Narlumosbart
  • HY-123205

    KW-4354

    Histamine Receptor P2X Receptor 5-HT Receptor Apoptosis PERK p38 MAPK COX Inflammation/Immunology
    Oxatomide (KW-4354) is an orally active dual antagonist of the H1-histamine receptor and the P2X7 receptor, as well as an inhibitor of serotonin. Oxatomide possesses antihistaminic, antiallergic and anti-inflammatory activities. Oxatomide can be used in the research of allergic diseases .
    Oxatomide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: